

Feng Wang*, Lun-Hua Shen, Jin-Ke Jiang and Nian-gen Chen

Crystal structure of (*E*)-1-(2-cyano-3-oxo-1-phenylprop-1-en-1-yl)-3,7-diphenylindolizine-6-carbonitrile, C₃₁H₁₉N₃O




Table 1: Data collection and handling.

Crystal:	Colourless block
Size:	0.25 × 0.23 × 0.20 mm
Wavelength:	Mo K α radiation (0.71073 Å)
μ :	0.08 mm ⁻¹
Diffractometer, scan mode:	Bruker APEX-II, φ and ω
$\theta_{\max}$, completeness:	25.0°, 99%
$N(hkl)_{\text{measured}}$, $N(hkl)_{\text{unique}}$, R_{int} :	5907, 4060, 0.017
Criterion for I_{obs} , $N(hkl)_{\text{gt}}$:	$I_{\text{obs}} > 2 \sigma(I_{\text{obs}})$, 3168
$N(\text{param})_{\text{refined}}$:	316
Programs:	Bruker [1], SHELX [2, 3]

Table 2: Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å²).

Atom	x	y	z	$U_{\text{iso}}^*/U_{\text{eq}}$
C1	0.3097(2)	0.40101(16)	0.56440(12)	0.0357(4)
C2	0.3088(2)	0.52698(17)	0.53712(12)	0.0348(4)
C3	0.4106(2)	0.64391(17)	0.60777(12)	0.0357(4)
H3	0.420844	0.726881	0.590869	0.043*
C4	0.5000(2)	0.64362(16)	0.70451(12)	0.0343(4)
C5	0.3957(2)	0.39959(17)	0.65828(12)	0.0360(4)
H5	0.395031	0.317674	0.673737	0.043*
C6	0.2217(2)	0.26982(19)	0.49658(13)	0.0443(5)
C7	0.2037(2)	0.53535(17)	0.44035(12)	0.0351(4)
C8	0.1603(2)	0.44195(19)	0.34975(13)	0.0454(5)
H8	0.197771	0.370190	0.347888	0.054*
C9	0.0619(3)	0.4549(2)	0.26253(14)	0.0565(6)
H9	0.032152	0.390412	0.203474	0.068*
C10	0.0075(3)	0.5620(2)	0.26212(15)	0.0562(5)
H10	-0.056885	0.570624	0.203148	0.067*
C11	0.0506(3)	0.6568(2)	0.35125(15)	0.0507(5)
H11	0.015991	0.730115	0.351717	0.061*
C12	0.1448(2)	0.64261(19)	0.43951(14)	0.0445(5)
H12	0.169470	0.705002	0.499004	0.053*
C13	0.5818(2)	0.53816(17)	0.82828(12)	0.0360(4)
C14	0.6653(2)	0.67569(17)	0.86180(12)	0.0372(4)
H14	0.742133	0.717667	0.924186	0.045*
C15	0.6174(2)	0.74494(17)	0.78735(12)	0.0358(4)
C16	0.5843(2)	0.42703(17)	0.88014(12)	0.0359(4)
C17	0.4378(2)	0.31372(18)	0.87128(13)	0.0432(4)
H17	0.334273	0.307513	0.831908	0.052*
C18	0.4458(3)	0.21090(19)	0.92069(14)	0.0473(5)
H18	0.348225	0.135559	0.913292	0.057*
C19	0.5980(3)	0.2198(2)	0.98081(14)	0.0508(5)

<https://doi.org/10.1515/ncrs-2020-0106>

Received February 23, 2020; accepted March 23, 2020; available online April 10, 2020

Abstract

C₃₁H₁₉N₃O, triclinic, $P\bar{1}$ (no. 2), $a = 8.672(5)$ Å, $b = 10.725(6)$ Å, $c = 13.886(8)$ Å, $\alpha = 97.550(9)^\circ$, $\beta = 101.415(9)^\circ$, $\gamma = 109.603(9)^\circ$, $V = 1164.9(12)$ Å³, $Z = 2$, $R_{\text{gt}}(F) = 0.0439$, $wR_{\text{ref}}(F^2) = 0.1288$, $T = 296$ K.

CCDC no.: 1985765

The molecular structure is shown in the figure. Table 1 contains crystallographic data and Table 2 contains the list of the atoms including atomic coordinates and displacement parameters.

***Corresponding author: Feng Wang**, College of Biology and Pharmaceutical Engineering, Jilin Agricultural and Science Technology University, 132101 Jilin Province, P.R. China, e-mail: jlnkwf@126.com. <https://orcid.org/0000-0001-8947-9297>

Lun-Hua Shen: Mianyang Vendinor Pharmaceutical Ltd, 621010 Sichuan Province, P.R. China

Jin-Ke Jiang: College of Biology and Pharmaceutical Engineering, Jilin Agricultural and Science Technology University, 132101 Jilin Province, P.R. China

Nian-gen Chen: School of Pharmacy, Hainan Medical University, 571199 Hainan Province, P.R. China

Table 2 (continued)

Atom	x	y	z	U _{iso} */U _{eq}
H19	0.603370	0.150096	1.013108	0.061*
C20	0.7427(3)	0.3330(2)	0.99277(14)	0.0526(5)
H20	0.844774	0.339955	1.034441	0.063*
C21	0.7368(2)	0.43543(19)	0.94345(13)	0.0462(5)
H21	0.834958	0.510892	0.952215	0.055*
C22	0.6735(2)	0.89055(16)	0.79191(12)	0.0349(4)
C23	0.5451(2)	0.93981(16)	0.73936(12)	0.0356(4)
C24	0.3809(2)	0.89496(18)	0.75326(13)	0.0419(4)
H24	0.356054	0.841095	0.799677	0.050*
C25	0.2554(2)	0.9298(2)	0.69880(14)	0.0491(5)
H25	0.147203	0.899307	0.708901	0.059*
C26	0.2902(3)	1.0098(2)	0.62945(15)	0.0548(5)
H26	0.205381	1.032254	0.592411	0.066*
C27	0.4524(3)	1.0565(2)	0.61536(15)	0.0554(5)
H27	0.476188	1.111245	0.569364	0.067*
C28	0.5796(2)	1.02198(18)	0.66952(14)	0.0463(5)
H28	0.687690	1.053463	0.659383	0.056*
C29	0.8372(2)	0.97846(17)	0.83992(13)	0.0386(4)
C30	0.9683(2)	0.92835(18)	0.87584(14)	0.0435(4)
C31	0.8933(2)	1.12735(19)	0.85718(14)	0.0479(5)
H31	0.810771	1.164302	0.842233	0.057*
N1	0.1564(2)	0.16341(18)	0.44536(13)	0.0675(6)
N2	0.48267(17)	0.51762(13)	0.72977(10)	0.0341(3)
N3	1.0779(2)	0.89456(18)	0.90389(14)	0.0591(5)
O1	1.03928(18)	1.20472(14)	0.88948(12)	0.0663(4)

Source of material

Add phenylmagnesium bromide (24 mmol) to 1-benzyl-3-cyano-4-phenylpyridine bromide (20 mmol) under dark conditions [4–6], Stirring was continued for 20 min on cooling until RT was reached. Then wash the solution three times with water. After drying of the organic layer over sodium sulfate the solution was filtered and evaporated to dryness. The resulting oil was purified by silica gel column chromatography using a mixture of petroleum ether and ethyl acetate (10:1) as eluent (1-benzyl-3-cyano-4-phenyl-1,4-dihydropyridine). The final product is synthesized by the literature known method [7]. 1-Benzyl-3-cyano-4-phenyl-1,4-dihydropyridine (0.2 mmol) was added to 2-methoxy-3,6-diphenylhexyl-4-nitrile (0.2 mmol), tris(dibenzylideneacetone)dipalladium (0.01 mmol), 10% bis[(2-diphenylphosphino)phenyl] ether (DPE-Phos, 0.02 mmol), potassium carbonate (0.4 mmol) as catalyst, and dimethyl sulfoxide (2 mL). The mixture was reacted for 16 h at 140 °C under nitrogen atmosphere. Finally, the resulting solution was evaporated to dryness *in vacuo* to give the title compound as colorless crystals.

Experimental details

All hydrogen atoms were placed in the calculated positions.

Comment

Although major part of the research on indolizine derivatives is focused on anti-cancer drug discovery, these derivatives have also been screened for different biological and medicinal activities [8–10]. For most drugs, there is a problem of poor fat solubility. In this study, appropriate introduction of some lipophilic groups, such as phenyl groups at the core of indolizine can increase the lipid solubility of the derivatives and promote the absorb.

It is not difficult to see from the structure that the pyridine ring is selectively cyclized with a carbon-carbon triple bond under the palladium catalysis, and finally an indole compound is formed. It is worth noting that the three phenyl rings are not in a plane. The bond lengths and angles are in the expected ranges.

References

1. Bruker. SAINT. Version 8.23B. Bruker AXS Inc., Madison, WI, USA (2013).
2. Sheldrick, G. M.: Crystal structure refinement with SHELXL. *Acta Crystallogr.* **C71** (2015) 3–8.
3. Sheldrick, G. M.: A short history of SHELX. *Acta Crystallogr.* **A64** (2008) 112–122.
4. Robert, E. L.; Edward, W.: Reaction of organometallic reagents with pyridinium ions. *J. Org. Chem.* **36** (1970) 772–777.
5. Paul, C.; Gargiulo, S.; Opperman, J.; Lavandera, I.; Gotor-Fernandez, V.; Gotor, V.; Taglieber, A.; Arends, I.; Hollmann, F.: Mimicking nature: synthetic nicotinamide cofactors for C=C bioreduction using enoate reductases. *Org. Lett.* **1** (2013) 180–183.
6. Chen, J.; Zhu, H.; Zhang, M.; Xu, W.; Wang, C.; Zhang, F.: Crystal structure of 1-benzyl-3-cyano-6-phenyl-1,2-dihydropyridine, C₁₉H₁₆N₂. *Z. Kristallogr. NCS* **3** (2019) 519–520.
7. Wu, T.; Chen, M.; Yang, Y.: Synthesis of indolizines *via* palladium catalyzed annulation of propargyl carbonates and 2-(pyridin-2-yl) acetonitrile derivatives. *J. Org. Chem.* **20** (2017) 11304–11309.
8. Sharma, V.; Kumar, V.: Indolizine a biologically active moiety. *Med. Chem. Res.* **8** (2014) 3593–3606.
9. James, D.; Koya, K.; Li, H.; Liang, G.; Xia, Z.; Ying, W.; Wu, Y.; Sun, L.: Indole-and indolizine-glyoxylamides displaying cytotoxicity against multidrug resistant cancer cell lines. *Bioorg. Med. Chem. Lett.* **6** (2008) 1784–1787.
10. Weide, T.; Arve, L.; Prinz, H.; Waldmann, H.; Kessler, H.: 3-Substituted indolizine-1-carbonitrile derivatives as phosphatase inhibitors. *Bioorg. Med. Chem. Lett.* **1** (2006) 59–63.